NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

Has The Recent ImmunityBio Share Price Rebound Created An Opportunity In 2025?

Wondering if ImmunityBio at around $2.36 is a speculative trap or a misunderstood bargain? You are not alone, and that is exactly what this breakdown is here to unpack. Despite a bruising longer term record, with the share price down about 17.8% over the last year and 63.4% over three years, the stock has shown signs of life recently, gaining roughly 3.1% in the past week and 14.6% over the last month, while still sitting 8.2% lower year to date. Those moves have come as investors continue...
NasdaqCM:CAPR
NasdaqCM:CAPRBiotechs

Assessing Capricor Therapeutics After a 343% Surge and Bullish DCF Valuation Estimate

If you have been wondering whether Capricor Therapeutics is still a smart buy after its big run, you are not alone. This stock has quickly moved from under the radar to front and center on a lot of watchlists. The share price has dipped 3.2% over the last week, but that small pullback sits on top of a 343.3% gain in the last month and a 96.2% return over the past year, with long term holders still up 593.9% over 3 years and 524.0% over 5 years. Behind those moves, investors have been...
NYSE:MAIN
NYSE:MAINCapital Markets

Does Main Street Capital’s 2025 Valuation Reflect Its Strong Multi Year Share Price Gains?

If you have ever looked at Main Street Capital and wondered whether the current price really reflects its underlying value, this breakdown is for you. The stock has climbed to around $62.05, delivering about 2.2% over the last week, 4.9% in the last month, 4.7% year to date, and 19.9% over the past year, with multi year gains of 114.1% over 3 years and 190.8% over 5 years reshaping how investors see its potential. Recent headlines have focused on Main Street Capital expanding its portfolio...
NasdaqGS:TER
NasdaqGS:TERSemiconductor

Teradyne (TER): Gauging Valuation After New U.S. Robotics Operations Hub in Michigan

Teradyne (TER) just put a bigger flag in U.S. manufacturing, with Teradyne Robotics planning a new operations hub in Wixom, Michigan, to build cobots and support customers across North America. See our latest analysis for Teradyne. The Wixom hub builds on a big year for Teradyne, where enthusiasm around AI driven semiconductor demand and robotics has helped drive a roughly 72 percent 3 month share price return and a strong multi year total shareholder return, even after the latest pullback to...
NasdaqGM:DJT
NasdaqGM:DJTInteractive Media and Services

Trump Media & Technology Group (DJT): Revisiting Valuation After a Steep Three-Month Share Price Slide

Recent stock performance and context Trump Media and Technology Group (DJT) has been drifting lower, with the stock down about 16% over the past month and more than 37% over the past 3 months. This has prompted fresh questions about valuation and trajectory. See our latest analysis for Trump Media & Technology Group. Zooming out, the share price has slid to about $10.65 and the sharp year to date share price return decline, alongside a steep 1 year total shareholder loss, suggests momentum is...
NYSE:NGVC
NYSE:NGVCConsumer Retailing

Natural Grocers (NGVC) Earnings: Margin Improvement Challenges Cautious Profitability Narratives

Natural Grocers by Vitamin Cottage (NGVC) has wrapped up FY 2025 with fourth quarter revenue of $336.1 million and basic EPS of $0.51, alongside trailing twelve month revenue of about $1.3 billion and EPS of $2.02. Over the last few quarters the company has seen revenue move from $322.7 million in Q4 2024 to $336.1 million in Q4 2025, while quarterly EPS stepped up from $0.40 to roughly the low $0.50s as net income climbed from $9.0 million to $11.8 million. With net margin rising from 2.7%...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead (GILD) Valuation Check as New Yescarta Data Reinforces CAR T Role in Second-Line Lymphoma

Kite, a Gilead Sciences (GILD) company, just released new analysis showing its CAR T therapy Yescarta delivers consistent benefits as a second line option for difficult large B cell lymphoma cases. See our latest analysis for Gilead Sciences. That stronger oncology story is quietly reshaping how investors see Gilead, with the share price at $120.4 after a softer recent patch but a robust year to date share price return of 31.04 percent, backed by a 1 year total shareholder return of 33.86...
NYSE:BTU
NYSE:BTUOil and Gas

Peabody Energy (BTU): Revisiting Valuation After a 58% Three-Month Share Price Rebound

Why Peabody Energy is Back on Watchlists Peabody Energy (BTU) has quietly turned into a strong performer over the past 3 months, with the stock up roughly 58%, even as its latest annual results still show a small net loss. See our latest analysis for Peabody Energy. Zooming out, that recent strength comes after a choppy year. Peabody’s share price is now at $29.15, with momentum clearly rebuilding following a strong 90 day share price return alongside a solid five year total shareholder...
NYSE:LLY
NYSE:LLYPharmaceuticals

Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far?

Wondering if Eli Lilly is still worth buying after its monster run, or if the upside has already been priced in? You are not alone, and that is exactly what this article aims to unpack. The stock has climbed 1.7% over the last week, 1.0% in the past month, and is up a hefty 32.1% year to date, building on a 31.2% gain over the last year and an astonishing 531.7% over five years. A big part of this momentum has been driven by excitement around Eli Lilly's obesity and diabetes treatments,...
NYSE:ABR
NYSE:ABRMortgage REITs

Assessing Arbor Realty Trust After a Sharp 2024 Slide and Earnings Based Valuation Gap

Wondering if Arbor Realty Trust at around $8.87 is a beaten down opportunity or a value trap? Let us unpack what the numbers are really saying about the stock. Despite a modest 0.2% gain over the last 7 days, the share price is still down 3.8% over 30 days, 35.6% year to date, and 30.6% over the past year, with only a 6.9% gain over five years. This naturally raises questions about whether the market has become too pessimistic. Recently, the stock has been in the spotlight as investors...
NasdaqGM:FEIM
NasdaqGM:FEIMElectronic

Frequency Electronics (FEIM) Q2 2026: 30% TTM Net Margin Reinforces Bullish Profitability Narrative

Frequency Electronics (FEIM) just posted Q2 2026 results with revenue of about $17.1 million and basic EPS of roughly $0.18, putting fresh numbers on the board for both the top and bottom line. The company has seen quarterly revenue move from around $15.8 million in Q2 2025 to $17.1 million this quarter, while basic EPS has shifted from approximately $0.28 to $0.18 over the same period, against a trailing-12-month net income backdrop of about $21.0 million. Taken together, the latest print...
NasdaqGM:LUNR
NasdaqGM:LUNRAerospace & Defense

Intuitive Machines (LUNR) Is Up 6.8% After Buying Lanteris To Become Full-Service Space Contractor

Earlier this month, Intuitive Machines acquired Lanteris Space Systems, moving to offer end-to-end space services spanning multiple orbital regimes and mission types. This move effectively recasts Intuitive Machines as a full-service space contractor, broadening its role across civil, defense, and commercial space programs. We’ll now examine how the Lanteris acquisition, and Intuitive Machines’ push into full-service space contracting, reshapes its investment narrative. AI is about to change...
NasdaqGS:FISV
NasdaqGS:FISVDiversified Financial

Did BAFS–Portico Integration Just Recast Fiserv's (FISV) Credit Union Lending Tech Narrative?

In early December 2025, Business Alliance Financial Services (BAFS) announced its integration with Fiserv’s Portico® account processing system, giving Portico-using credit unions broader access to BAFS’ BLAST® commercial loan origination and accounting platform across the full lending lifecycle. This integration underscores how Fiserv’s core processing relationships can deepen its role in commercial lending technology for credit unions, potentially enhancing client stickiness and cross‑sell...
NasdaqGS:QCOM
NasdaqGS:QCOMSemiconductor

Is Qualcomm Still Attractively Priced After Its Edge AI Expansion and Three Year 66% Surge

If you are wondering whether QUALCOMM at around $178 a share is still a smart buy or if the best gains are already behind it, you are not alone. That question is exactly what this valuation deep dive will unpack. The stock has climbed about 2.0% over the last week, 0.9% over the past month, and is up 16.0% year to date. This adds to a solid 15.0% gain over the last year and a 66.6% gain over three years. Recent headlines have focused on QUALCOMM doubling down on AI at the edge, from...
NasdaqGS:AVGO
NasdaqGS:AVGOSemiconductor

Broadcom (AVGO) Margin Surge to 36.2% Reinforces Bullish AI Profitability Narrative

Broadcom (AVGO) kicked off FY 2025 with fiscal Q4 revenue of about $18.0 billion and basic EPS of $1.80, capping off a year in which trailing 12 month revenue reached roughly $63.9 billion and EPS climbed to $4.91 as reported earnings jumped 275.4% with net margins advancing to 36.2% from 12% the prior year. The company has seen revenue move from around $51.6 billion on a trailing 12 month basis in late 2024 to $63.9 billion by Q4 2025, while net income over the same window expanded from $6.2...
NasdaqGS:EQIX
NasdaqGS:EQIXSpecialized REITs

Equinix (EQIX) Valuation Check as Long-Serving CFO Announces Retirement and Transition to Special Advisor

Equinix (EQIX) just put a major leadership transition on the calendar, with longtime CFO Keith Taylor planning to retire in 2026 while staying on as a Special Advisor to support the handover. See our latest analysis for Equinix. The leadership change comes at a tricky moment for sentiment, with the share price at $750.32 and a year to date share price return of negative 20.54 percent. Even though the three year total shareholder return remains positive, this suggests longer term momentum is...
NYSE:GIS
NYSE:GISFood

Has General Mills’ 26% Share Price Slide in 2025 Created an Opportunity?

Wondering if General Mills at around $46.69 is a bargain hiding in plain sight or a classic value trap in the making? This article is designed to help you figure that out with a clear, valuation-first lens. Despite a modest 1.7% gain over the last 7 days and a flat 0.4% over 30 days, the stock is still down a steep 26.5% year to date and 26.8% over the last year, which naturally raises questions about whether sentiment has overshot the fundamentals. Recently, investors have been rethinking...
NYSE:MUX
NYSE:MUXMetals and Mining

How McEwen’s (MUX) New Drill Results and Pit Strategy Could Reshape Its Mine Life Profile

McEwen Inc. recently reported progress across several core assets, including completing the 2025 drill program at Lookout Mountain in Nevada and releasing new high‑grade drill results from the Froome Mine at the Fox Complex in Ontario, which together aim to increase resources, extend mine lives and support potential production growth. A distinctive aspect of these updates is the combination of near‑mine extensions at Froome West and early work to merge multiple pits at Unity Ridge, which...
NYSE:HIMS
NYSE:HIMSHealthcare

Is Hims & Hers Health Still Attractive After Its 450% Surge and Telehealth Expansion?

Wondering if Hims & Hers Health is still a smart buy after its big run, or if the easy money has already been made? You are not alone, and this article is going to unpack exactly what the current price is really baking in. Even after a recent pullback of around 5.1% over the last week and 4.6% over the past month, the stock is still up 47.7% year to date and a massive 450.4% over three years. This tells you the market has already rewritten its expectations in a big way. That surge in...
NasdaqGS:ABNB
NasdaqGS:ABNBHospitality

Is It Too Late to Consider Airbnb After Recent Share Price Rebound?

Wondering if Airbnb at around $128 a share is still a good deal or if the easy money has already been made? This article breaks down what the current price really implies about its future. Despite being down about 2.4% year to date and 2.0% over the last year, the stock has quietly climbed 3.3% in the past week and 5.5% over the last month, hinting that investor sentiment may be starting to turn. That recent strength has come as investors refocus on travel demand normalizing, ongoing product...
NYSE:TOST
NYSE:TOSTDiversified Financial

Has Toast’s Rally Stalled After A 7.5% Slide And Lofty Valuation Multiples?

If you are wondering whether Toast is actually a bargain at today’s prices or if the easy money has already been made, you are not alone. That is exactly what we are going to unpack. The stock has slipped recently, down about 1.1% over the last week, 8.0% over the last month and 7.5% over the past year, even though it is still up around 88.1% over three years. Much of the recent share price action has been driven by changing market sentiment toward high growth, software enabled payment...
NYSE:PLNT
NYSE:PLNTHospitality

What Planet Fitness (PLNT)'s US$750 Million Fixed-Rate Refinancing Means For Shareholders

Planet Fitness, Inc. recently completed a refinancing, pricing US$750 million of Series 2025-1 Class A-2 fixed-rate senior secured notes across five- and seven-year tranches, and adding a new US$75 million variable funding note facility through a bankruptcy-remote subsidiary. The transaction not only replaces existing 2022-1 debt but also frees up cash for general corporate purposes, including potential share repurchases, which could influence the company’s balance sheet mix and capital...